Her Majesty's Ship

Global Hot Melt Adhesives Market Analysis/Growth Opportunities Report 2022: Strategic Partnering and Inorganic Growth Strategies for Developing New Business Strengths - ResearchAndMarkets.com

Retrieved on: 
Monday, December 12, 2022
Chemicals, Plastics, Manufacturing, Polyurethane, VOC, Chemistry, Polyamide, Bookbinding, Textile, Her Majesty's Ship, Extravehicular activity, HMA, Electronics, Russo-Ukrainian War, COVID-19, Transport, Adhesive, Drug

The "Global Hot Melt Adhesives Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hot Melt Adhesives Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The global HMAs market is challenged by the rising need for innovative chemistries that will cater to customers' unmet needs, such as bio-based adhesives, biodegradable formulations, de-bondable HMAs, and heat-resistant adhesives.
  • Development of new, high-performance, and innovative chemistries and other factors combined will contribute to higher prices and thereby revenue growth.
  • Hot melt adhesives (HMAs) are a major component in packaging, nonwovens, furniture, automotive, construction, bookbinding, and other applications.

Advantages of Hot Melt Adhesives (HMAs) Drive the Industry's Growth

Retrieved on: 
Wednesday, November 23, 2022
HMA, VOC, Nutrition, Growth, Recycling, Research, Frost, Organization, Fortune 1000, Carbon footprint, Her Majesty's Ship, R, Renewable energy

SAN ANTONIO, Nov. 23, 2022 /PRNewswire/ -- The market for hot melt adhesives (HMAs) will rise by 2028 due to its multiple advantages to customers across industries, finds Frost & Sullivan's recent analysis, Global Hot Melt Adhesives Growth Opportunities. HMAs have several benefits over other adhesive formulations, such as faster drying and setting, cost-effectiveness, and low volatile organic compound (VOC) emissions. The global HMAs market is expected to garner $13.81 billion in revenue by 2028 from $9.03 billion in 2021, growing at a compound annual growth rate (CAGR) of 6.3%.

Key Points: 
  • The global HMAs market is expected to garner $13.81 billion in revenue by 2028, registering growth at a CAGR of 6.3%, says Frost & Sullivan
    SAN ANTONIO, Nov. 23, 2022 /PRNewswire/ --The market for hot melt adhesives (HMAs) will rise by 2028 due to its multiple advantages to customers across industries, finds Frost & Sullivan's recent analysis, Global Hot Melt Adhesives Growth Opportunities.
  • The global HMAs market is expected to garner $13.81 billion in revenue by 2028 from $9.03 billion in 2021, growing at a compound annual growth rate (CAGR) of 6.3%.
  • Global Hot Melt Adhesives Growth Opportunities is the latest addition to Frost & Sullivan's Chemicals, Materials & Nutrition research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
  • For over six decades, Frost & Sullivan has helped build sustainable growth strategies for Fortune 1000 companies, governments, and investors.

Advantages of Hot Melt Adhesives (HMAs) Drive the Industry's Growth

Retrieved on: 
Wednesday, November 23, 2022
HMA, VOC, Nutrition, Growth, Recycling, Research, Frost, Organization, Fortune 1000, Carbon footprint, Her Majesty's Ship, R, Renewable energy

SAN ANTONIO, Nov. 23, 2022 /PRNewswire/ -- The market for hot melt adhesives (HMAs) will rise by 2028 due to its multiple advantages to customers across industries, finds Frost & Sullivan's recent analysis, Global Hot Melt Adhesives Growth Opportunities. HMAs have several benefits over other adhesive formulations, such as faster drying and setting, cost-effectiveness, and low volatile organic compound (VOC) emissions. The global HMAs market is expected to garner $13.81 billion in revenue by 2028 from $9.03 billion in 2021, growing at a compound annual growth rate (CAGR) of 6.3%.

Key Points: 
  • The global HMAs market is expected to garner $13.81 billion in revenue by 2028, registering growth at a CAGR of 6.3%, says Frost & Sullivan
    SAN ANTONIO, Nov. 23, 2022 /PRNewswire/ --The market for hot melt adhesives (HMAs) will rise by 2028 due to its multiple advantages to customers across industries, finds Frost & Sullivan's recent analysis, Global Hot Melt Adhesives Growth Opportunities.
  • The global HMAs market is expected to garner $13.81 billion in revenue by 2028 from $9.03 billion in 2021, growing at a compound annual growth rate (CAGR) of 6.3%.
  • Global Hot Melt Adhesives Growth Opportunities is the latest addition to Frost & Sullivan's Chemicals, Materials & Nutrition research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
  • For over six decades, Frost & Sullivan has helped build sustainable growth strategies for Fortune 1000 companies, governments, and investors.

The Worldwide Hot Melt Adhesives Industry is Expected to Reach $11.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022
Chemicals, Plastics, Manufacturing, Row, EVA, Vegetable, Agriculture, Paper, USD, Poultry, Her Majesty's Ship, Cosmetics, SBC, Adhesive, APAO, MPO, Furniture, CAGR, PU, Meat, Printing, Seafood, Growth, Transport, Cardboard, HMA, Bookbinding

The HMA market is projected to grow from USD 9.1 Billion in 2022 to USD 11.4 Billion by 2027, at a CAGR of 4.8% between 2022 and 2027.

Key Points: 
  • The HMA market is projected to grow from USD 9.1 Billion in 2022 to USD 11.4 Billion by 2027, at a CAGR of 4.8% between 2022 and 2027.
  • The opportunities related to increased use of HMA in road marking applications are driving the growth of the market.
  • Packaging solutions application segment is estimated to be the largest segment of the HMA market.
  • The packaging application of HMAs includes carton boxes, envelopes, carton closure, cups, flexible packaging, specialty packaging, bags, and processed food products.

Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

Retrieved on: 
Thursday, March 10, 2022
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Patient, Risk, U.S. Securities and Exchange Commission, Survival, Pharmacokinetics, Telephone, AML, Health, NDA, Private Securities Litigation Reform Act, GAAP, MDS, MAA, Depreciation, Vii, Acute myeloid leukemia, TI, Disease, OS, HR, Lymphatic system, New Drug Application, Apoptosis, Safety, Her Majesty's Ship, Company, JAK, ESA, FDA, Imetelstat, MD Anderson Cancer Center, Intellectual property, IMPRESS, MF, Fast Track, Clinical trial, Annual report, Research, Security (finance), RBC, Corporation, Income, ID, Nasdaq, Webcast, Form 10-K, Asterias, Lineage Cell Therapeutics, Ix, COVID-19, Geron Corporation, Microdeletion syndrome, Pharmaceutical industry, Medical device, Medicine, Health insurance, Lithium, Animal, Video game, EU, Imetelstat, IMerge Phase 3, IMpactMF, Geron, IMETELSTAT, IMERGE PHASE 3, IMPACTMF, GERON

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2021.
  • For the fourth quarter of 2021, the Company reported a net loss of $32.0 million, or $0.10 per share, compared to $23.8 million, or $0.07 per share, for the fourth quarter of 2020.
  • ET on Thursday, March 10, 2022 to discuss business updates, expected upcoming milestones and fourth quarter and full year 2021 financial results.
  • Geron encourages investors to carefully consider the Companys results under GAAP, as well as the supplemental non-GAAP financial information, to more fully understand Gerons business.

MLT Analytics Report: Polyolefin Elastomer Market Propelled by Solar, Auto Lightweighting, Monomaterial Packaging

Retrieved on: 
Tuesday, March 8, 2022
Other Manufacturing, Research, Technology, Packaging, Engineering, Chemicals, Plastics, Other Technology, Manufacturing, Data Management, Science, Plant, Artificial intelligence, Hygiene, Industry, Machine learning, Persistent organic pollutant, LG Chem, Electricity, Plastic, Solution, Growth, Multimedia, US, Elastomer, Food, Her Majesty's Ship, ML, Dow Chemical Company, Mitsui Chemicals, MLT, LGBT slang, Borealis, ExxonMobil, CAGR, Engineering, AI, Technology, PP, SABIC, EVA, POE, Paraffin wax

View the full release here: https://www.businesswire.com/news/home/20220308005102/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220308005102/en/
    POE and EVA will coexist as solar panel encapsulant materials, with the former enjoying stronger growth rates.
  • (Image: MLT Analytics)
    2021 was a breakout year for POE usage in solar module encapsulation, says MLT Analytics CEO and co-founder Stephen Moore.
  • Footwear and holt melt adhesives (HMAs) are other areas where POE suppliers plan to pursue market share, again at the expense of EVA.
  • POEs also bring several advantages over incumbent EVA solutions for adhesion, particularly in end-of-line paperboard and carton board packaging.

Biosight Reports Final Primary Endpoint Data from Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

Retrieved on: 
Thursday, January 6, 2022
Well, EMA, ELN, Safety, Toxicity, American Society of Hematology, CR, HMA, ECOG, Feinberg School of Medicine, Therapy, Patient, Bone marrow, Pharmacokinetics, Lymphatic system, Myelodysplastic syndrome, ASH, Treatment, Society, Disorder, Asparagine, AML, Cytarabine, Fast track (FDA), Combination therapy, FDA, Induction chemotherapy, Population, GFM, GLOBE, MDS, Her Majesty's Ship, Metabolism, Pharmaceutical industry, Medical device, Medicine, European

AIRPORT CITY, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) --  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced final results for the primary study endpoint, complete remission (CR), from the Company’s Phase 2b clinical trial evaluating single-agent aspacytarabine (BST-236) as a first-line acute myeloid leukemia (AML) therapy for patients unfit for standard induction chemotherapy. These results, presented at the 2021 American Society of Hematology (ASH) Annual Meeting held in December, 2021, demonstrated efficacy, safety, and tolerability of BST-236 as a monotherapy in treatment of newly-diagnosed AML patients unfit for standard induction therapy.

Key Points: 
  • Key highlights from the poster presentation titled, Aspacytarabine (BST-236) as Monotherapy is Safe, Well-tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy.
  • For more information regarding the Phase 2b clinical study of BST-236, please visit www.clinicaltrials.gov .
  • Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders.
  • Aspacytarabine is currently being investigated as a single agent in a Phase 2b clinical trial, which recently completed enrollment and primary endpoint analysis, for the first-line treatment of AML.